Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free APLMW Stock Alerts

Apollomics (APLMW) Financials

Apollomics logo
$0.01 0.00 (-15.48%)
As of 03:57 PM Eastern
Compare
Annual Income Statements for Apollomics

Annual Income Statements for Apollomics

This table shows Apollomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -44 -57 -51 -96 -54 -11
Consolidated Net Income / (Loss)		 -44 -57 -50 -96 -54 -11
Net Income / (Loss) Continuing Operations		 -44 -57 -50 -96 -54 -11
Total Pre-Tax Income 		-45 -57 -50 -96 -54 -11
Total Operating Income		 -43 -54 -45 -55 -55 -11
Total Gross Profit		 0.07 -0.08 -0.09 -0.15 0.00 8.50
Total Revenue		 0.14 0.00 0.00 0.00 0.00 8.50
Operating Revenue		 - - - 0.00 0.00 8.50
Total Cost of Revenue		 0.07 0.08 0.09 0.15 0.00 0.00
Total Operating Expenses		 43 54 45 55 55 20
Selling, General & Admin Expense		 11 15 9.95 21 18 12
Research & Development Expense		 31 36 35 34 25 5.53
Impairment Charge		 1.00 3.00 0.00 0.00 13 1.72
Total Other Income / (Expense), net		 -1.14 -3.47 -4.84 -41 1.74 0.25
Other Income / (Expense), net		 -1.25 -3.47 -5.16 -41 1.74 0.25
Income Tax Expense		 -0.09 0.00 0.00 0.01 0.26 0.00
Preferred Stock Dividends Declared		 - - - - 0.00 0.00

Quarterly Income Statements for Apollomics

No quarterly income statements for Apollomics are available.

Annual Cash Flow Statements for Apollomics

This table details how cash moves in and out of Apollomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 92 -104 3.73 1.98 -22 -2.24
Net Cash From Operating Activities		 84 -0.38 3.74 -0.95 -29 -2.30
Net Cash From Continuing Operating Activities		 84 -0.38 3.74 -0.95 -30 -2.30
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 -54 0.00
Depreciation Expense		 0.59 0.13 0.16 0.08 0.29 0.03
Amortization Expense		 0.02 0.02 0.02 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 119 -0.08 -0.09 -0.12 24 -0.07
Changes in Operating Assets and Liabilities, net		 -36 -0.45 3.65 -0.93 -0.83 -2.28
Net Cash From Investing Activities		 11 -0.03 -0.01 0.06 5.98 0.07
Net Cash From Continuing Investing Activities		 11 -0.03 -0.01 0.06 5.94 0.07
Sale of Property, Plant & Equipment		 - 0.00 0.00 0.06 0.00 0.05
Other Investing Activities, net		 0.01 -0.03 -0.01 0.01 - 0.02
Net Cash From Financing Activities		 126 -104 0.00 2.87 0.47 0.00
Net Cash From Continuing Financing Activities		 0.00 -104 0.00 2.87 0.34 0.00
Other Financing Activities, net		 - -104 0.00 2.87 0.70 0.00
Cash Interest Received		 0.33 0.47 0.43 0.82 - 0.15

Quarterly Cash Flow Statements for Apollomics

No quarterly cash flow statements for Apollomics are available.

Annual Balance Sheets for Apollomics

This table presents Apollomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 123 76 55 13 6.71
Total Current Assets		 99 33 40 10 6.05
Cash & Equivalents		 47 33 32 9.77 3.28
Plant, Property, & Equipment, net		 0.28 475 0.16 0.09 0.00
Plant, Property & Equipment, gross		 0.28 0.49 0.16 0.09 0.00
Total Noncurrent Assets		 16 -369 15 1.81 0.08
Intangible Assets		 15 15 15 1.74 0.00
Other Noncurrent Operating Assets		 1.15 -383 0.54 0.08 0.08
Total Liabilities & Shareholders' Equity		 -212 544 20 1.08 3.81
Total Liabilities		 1.04 5.56 4.99 1.07 3.79
Total Current Liabilities		 14 4.50 14 7.40 6.33
Short-Term Debt		 - 0.00 4.24 0.00 0.00
Other Current Liabilities		 0.51 - 0.16 0.23 0.21
Total Noncurrent Liabilities		 323 1.06 0.60 0.84 3.58
Total Equity & Noncontrolling Interests		 -213 538 41 4.86 -3.19
Total Preferred & Common Equity		 -213 538 15 0.01 0.02
Total Common Equity		 -225 -448 -647 0.01 0.02
Common Stock		 0.04 0.04 0.01 0.01 0.02

Quarterly Balance Sheets for Apollomics

No quarterly balance sheets for Apollomics are available.

Annual Metrics And Ratios for Apollomics

This table displays calculated financial ratios and metrics derived from Apollomics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 86,795,838.00 89,495,790.00 1,103,348.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 867,958.00 894,958.00 1,103,348.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -110.80 -60.18 -9.91
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -29.98% 11.84% -90.30% 44.52% 79.56%
EBIT Growth		 0.00% -28.55% 11.76% -89.82% 44.26% 79.60%
NOPAT Growth		 0.00% -24.26% 15.66% -20.85% -0.64% 79.78%
Net Income Growth		 0.00% -29.11% 12.32% -91.06% 44.00% 79.69%
EPS Growth		 0.00% -1,504.76% 12.32% -91.06% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -100.46% 1,076.50% -125.43% -2,922.40% 91.99%
Free Cash Flow Firm Growth		 0.00% 0.00% -22.02% 151.44% -152.43% 76.25%
Invested Capital Growth		 0.00% 0.00% 158.02% -85.32% -88.84% -107.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 50.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 -30,590.28% 0.00% 0.00% 0.00% 0.00% -128.12%
Operating Margin		 -30,147.22% 0.00% 0.00% 0.00% 0.00% -131.65%
EBIT Margin		 -31,013.19% 0.00% 0.00% 0.00% 0.00% -128.66%
Profit (Net Income) Margin		 -30,879.17% 0.00% 0.00% 0.00% 0.00% -128.69%
Tax Burden Percent		 99.81% 100.00% 100.00% 100.01% 100.48% 100.03%
Interest Burden Percent		 99.76% 100.00% 99.36% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,012.02%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 3,841.11%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -293.35%
Return on Equity (ROE)		 0.00% 26.97% -30.93% -33.19% -233.67% -1,305.37%
Cash Return on Invested Capital (CROIC)		 0.00% -391.09% -133.29% 82.96% -305.57% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -110.40%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -110.43%
Return on Common Equity (ROCE)		 0.00% 28.48% 63.94% 62.70% 3,279.32% -24.92%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 26.97% -9.35% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -38 -32 -38 -39 -7.83
NOPAT Margin		 -21,103.06% 0.00% 0.00% 0.00% 0.00% -92.15%
Net Nonoperating Expense Percent (NNEP)		 0.00% 15.57% -20.10% -24.94% -102.70% -4,853.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - -5.91% -84.15% -796.34% 245.70%
Cost of Revenue to Revenue		 50.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 7,668.75% 0.00% 0.00% 0.00% 0.00% 146.38%
R&D to Revenue		 21,834.03% 0.00% 0.00% 0.00% 0.00% 65.07%
Operating Expenses to Revenue		 30,197.22% 0.00% 0.00% 0.00% 0.00% 231.65%
Earnings before Interest and Taxes (EBIT)		 -45 -57 -51 -96 -54 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -57 -50 -96 -53 -11
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 793.26 982.24
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 982.24
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 2.43
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 47.54 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 2.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 14.68 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.11 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00
Financial Leverage		 0.00 -1.19 -0.57 -0.80 -0.64 -0.08
Leverage Ratio		 0.00 -0.58 0.61 0.23 1.49 11.82
Compound Leverage Factor		 0.00 -0.58 0.61 0.23 1.49 11.82
Debt to Total Capital		 0.00% -0.25% 0.18% 9.85% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 9.26% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% -0.25% 0.18% 0.58% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% -5.60% 94.91% 1,446.26% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 105.85% -83.09% -1,414.51% 0.23% -0.66%
Debt to EBITDA		 0.00 -0.01 -0.02 -0.05 0.00 0.00
Net Debt to EBITDA		 0.00 0.81 0.63 0.35 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.01 -0.02 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 -0.03 -0.12 0.00 0.00
Net Debt to NOPAT		 0.00 1.22 0.99 0.87 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.01 -0.03 -0.01 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -11.44 -8.34 -0.89
Noncontrolling Interest Sharing Ratio		 0.00% -5.58% 306.73% 288.94% 1,503.41% 98.09%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 7.33 7.27 2.95 1.39 0.96
Quick Ratio		 0.00 3.45 7.27 2.79 1.32 0.52
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -77 -94 49 -25 -6.04
Operating Cash Flow to CapEx		 58,110.42% 0.00% 0.00% 0.00% -143,715.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.86
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 178.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 40 102 15 1.67 -0.12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 10.98
Increase / (Decrease) in Invested Capital		 0.00 40 62 -87 -13 -1.79
Enterprise Value (EV)		 0.00 0.00 0.00 712 -1.04 17
Market Capitalization		 0.00 0.00 0.00 84 8.73 21
Book Value per Share		 $0.00 $0.00 $0.00 ($7.45) $0.00 $0.02
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($7.62) ($0.02) $0.02
Total Capital		 0.00 -212 539 46 4.86 -3.19
Total Debt		 0.00 0.53 0.99 4.50 0.00 0.00
Total Long-Term Debt		 0.00 0.53 0.99 0.27 0.00 0.00
Net Debt		 0.00 -46 -32 -33 -9.77 -3.28
Capital Expenditures (CapEx)		 0.14 0.00 0.00 -0.06 0.02 -0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 39 -4.50 -7.21 -6.90 -3.55
Debt-free Net Working Capital (DFNWC)		 0.00 86 28 31 2.87 -0.28
Net Working Capital (NWC)		 0.00 86 28 26 2.87 -0.28
Net Nonoperating Expense (NNE)		 14 20 18 58 15 3.11
Net Nonoperating Obligations (NNO)		 0.00 252 -436 -26 -3.19 3.07
Total Depreciation and Amortization (D&A)		 0.61 0.15 0.18 0.10 0.31 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -41.78%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -3.24%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -3.24%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($62.00) ($232.00) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 894.96K 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 894.96K 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -36 -32 -38 -30 -6.63
Normalized NOPAT Margin		 -20,616.94% 0.00% 0.00% 0.00% 0.00% -78.01%
Pre Tax Income Margin		 -30,938.19% 0.00% 0.00% 0.00% 0.00% -128.66%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Apollomics

No quarterly metrics and ratios for Apollomics are available.


Financials Breakdown Chart

Apollomics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Apollomics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Apollomics' net income appears to be on a downward trend, with a most recent value of -$10.94 million in 2025, falling from -$44.47 million in 2020. The previous period was -$53.86 million in 2024.

Apollomics' total operating income in 2025 was -$11.19 million, based on the following breakdown:
  • Total Gross Profit: $8.50 million
  • Total Operating Expenses: $19.69 million

Over the last 5 years, Apollomics' total revenue changed from $144 thousand in 2020 to $8.50 million in 2025, a change of 5,802.8%.

Apollomics' total liabilities were at $3.79 million at the end of 2025, a 254.4% increase from 2024, and a 265.3% increase since 2021.

In the past 4 years, Apollomics' cash and equivalents has ranged from $3.28 million in 2025 to $46.74 million in 2021, and is currently $3.28 million as of their latest financial filing in 2025.

Over the last 5 years, Apollomics' book value per share changed from 0.00 in 2020 to 0.02 in 2025, a change of 1.9%.


Related Companies

Financial statements for NASDAQ:APLMW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The Lithium Gold Rush Minted A New $1B Unicorn
The Lithium Gold Rush Minted A New $1B Unicorn This lithium producer surpassed a $1B private valuation, joi...
EnergyX | Sponsoredtc pixel
What Saudi Arabia just did to the dollar changes everything
In June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...
Golden Portfolio | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel